

Company number: 05498067  
Charity Number: 1113263

# International Federation of Gynecology and Obstetrics

Report and financial statements  
For the year ended 31 December 2024

Contents

For the year ended 31 December 2024

---

Reference and administrative information .....	1
Trustees' annual report .....	3
Independent auditor's report .....	19
Consolidated statement of financial activities .....	24
Balance sheets .....	25
Consolidated statement of cash flows .....	26
Notes to the financial statements .....	27

# International Federation of Gynecology and Obstetrics

## Reference and administrative information

For the year ended 31 December 2024

---

<b>Company number</b>	05498067
<b>Charity number</b>	1113263
<b>Registered office and operational address</b>	FIGO House, Suite 3 – Waterloo Court, 10 Theed Street, London SE1 8ST
<b>Country of registration</b>	England & Wales
<b>Country of incorporation</b>	United Kingdom
<b>Other name that the charitable company uses</b>	‘FIGO’

**Trustees** Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

Dr. Anne Beatrice Kihara	President
Dr. Edgar Ivan Ortiz Lizcano	Vice President
Prof. Shantha Kumari Sekaran	Honorary Treasurer
Dr. Ravi Chandran	Honorary Secretary
Prof. Frank Louwen	President Elect
Prof. Chiara Benedetto	Regional Trustee
Dr. Ernesto Castelazo	Regional Trustee
Dr. Blami Dao	Regional Trustee
Dr. Nestor Cesar Garello	Regional Trustee
Dr. Hrishikesh Pai	Regional Trustee

**Key management personnel**

Frances Longley	Chief Executive
Andrew Wiles	Chief Operating Officer
Christopher Horry	Director of Finance (until 28 February 2025)
Mark Lywood	Interim Head of Finance (until 16 July 2025)
Mehala Manimohan	Head of Finance (Started on 02 June 2025)

**Bankers** HSBC  
431 Oxford St, London W1C 2DA

**Solicitors** Davies & Partners  
57 Queen Anne Street, London W1G 9JR

Hempsons  
100 Wood Street, London, EC2V 7AN

# International Federation of Gynecology and Obstetrics

## Reference and administrative information

For the year ended 31 December 2024

---

<b>Auditor</b>	Sayer Vincent LLP Chartered Accountants and Statutory Auditor 110 Golden Lane LONDON EC1Y 0TG
----------------	---

## Trustees' report

### For the year ended 31 December 2024

---

The trustees present their report and the audited financial statements for the year ended 31 December 2024.

Reference and administrative information set out on pages 1 and 2 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association and the Statement of Recommended Practice – Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102.

## Objectives and activities

### Purposes and aims

**The charity's object**, for which FIGO is established, is restricted to the promotion of the health, wellbeing and rights of women worldwide by ensuring high standards in the practice of gynaecology and obstetrics for the benefit of the public.

**The main activities undertaken by the Charity** to further its charitable object for the public benefit include but are not limited to:

- Projects aimed at improving women's health, wellbeing and rights in low and middle-income countries including safe motherhood projects designed to reduce maternal mortality as well as sexual and reproductive health.
- The awarding of modest grants to FIGO Committees and National Societies to help in the promotion of the health and wellbeing of women worldwide and to improve the practice of gynecology and obstetrics.
- The organisation of international workshops and meetings.
- The production of educational material relating to women's health and the practice of obstetrics and gynaecology. These include webinars, Guidelines and other Best Practice advice.

**The activities of the subsidiary, FIGO Trading Limited**, include but are not limited to:

- The organisation of a World Congress of Gynecology and Obstetrics held every two years and regional congresses from time to time.
- The production of the International Journal of Gynecology & Obstetrics and other FIGO publications.

**Trustees' report**

**For the year ended 31 December 2024**

---

**The Charity is committed to:**

- Encouraging all efforts for raising the status of women and for advancing their role in all issues related to women's health.
- Promoting sexual and reproductive health and rights and services through education, research and advocacy that will support the provision of accessible, efficient, affordable, sustainable comprehensive reproductive health services.
- Accelerating its efforts and activities in respect of the United Nations' Sustainable Development Goals (SDG) and to achieving these targets especially in the area of safe motherhood and new-born health and gender equality.
- Continually upgrading the practice of gynaecology and obstetrics through research implementation, education and training and by maintaining the highest levels of professionalism and scientific and ethical standards.
- Improving communication with and between Society Member associations and building the capacities of those from low-resource countries through strengthening leadership, management, good practice and the promotion of policy dialogues.
- Strengthening capacities to enable Society Member associations to play a pivotal role in the development and implementation of sustainable programmes aimed at the improvement of care available to women and new-borns especially for poor and underserved populations. These include developing their abilities to advocate on behalf of women and those who care for them to policy makers at regional and national level.
- Recognising the importance of collaborative efforts for advancing women's health and rights, the Charity is committed to strengthening partnerships with other international professional organisations, UN agencies, and the public/private sector to achieve its objectives.

**Public Benefit Statement**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

The trustees review the aims, objectives and activities of the charity each year. This report looks at what the charity has achieved and the outcomes of its work in the reporting period. The

## Trustees' report

For the year ended 31 December 2024

---

trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help.

## Achievements and performance

The charity's main activities and who it tries to help are described below. All its charitable activities focus on the improvement of women's health and reproductive rights, the reduction of disparities in healthcare available to women and new-borns, as well as advancing the science and practice of gynaecology and obstetrics and are undertaken to further FIGO's charitable purposes for the public benefit.

The Charity is the only global organisation that brings together professional societies of obstetricians and gynaecologists from across the world. The Charity currently has Society Member associations in 139 countries/territories.

## Restricted projects

The Charity has been fortunate to receive a number of large grants to fund specific multi-year projects. These include projects aimed at improving the health and wellbeing of all women whether pregnant or non-pregnant and the services that support this in low- and middle-resource countries/territories. FIGO works with its Member associations to deliver improved health interventions or helps the Member associations build capacity and capability in a particular region or nation.

FIGO currently has a number of large projects in progress and received money to support its activities from donors totalling £2,165,873 during 2024 (2023: £2,836,221), including £613,317 (2023: £755,859) for the project relating to Advocating Safe Abortion, £290,315 (2023: £610,301) from donors to our Fistula Surgery Training Initiative, £434,940 (2023: £364,484) for our combatting Post-Partum Haemorrhage (PPH) projects, £101,457 (2023, nil) for the WHO funded project, Abortion and Contraception Care Together and £724,607 (2023: £1,100,802) for our FIGO Leadership Development Initiative (LDI:REACH) which is being sponsored by the Bill and Melinda Gates Foundation and aims to improve maternal and new-born health outcomes through advocacy and improved care in six countries.

These specific restricted projects are normally undertaken only as and when funding becomes available, and a project generally takes place over the term of the grant funding which is typically between one and three years. FIGO always aims to demonstrate positive and sustainable outcomes from its projects in improving maternal health. Evidence of strong outcomes can also help FIGO to secure further grant funding to expand a project's activities to other countries or to reach greater numbers of women and healthcare professionals.

Project activities are continuously monitored and evaluated in line with the project objectives and the requirements of the funder. During 2024, projects delivered the following significant achievements:

Trustees' report

For the year ended 31 December 2024

---

**Advocating for Safe Abortion Project (ASA)**

The Advocating for Safe Abortion Projects started in 2019 with funding from a large anonymous donor which ran through to end of 2023. During this time FIGO worked with 12 members societies in Africa and Latin America, as well as two regional federations (Société Africaine des Gynécologues et Obstétriciens – SAGO, and the East, Central and Southern African College of Obstetrics and Gynecology – ECSACOG) and associated Communities of Practice. Once this initial grant ended, new funding was provided by FJSI and the Hewlett foundation to continue the work in West Africa. The societies directly involved in the ASA Project during 2024 were Cameroon, Mali, and Burkina Faso.

As per the [Theory of Change](#), the ASA project continues to be structured around two core pillars. First is the strengthening of organisational and technical capacity of national societies of ObGyn to enable them to become national leaders in Sexual and Reproductive Health (SRHR), driving positive change within their local context. The second is engagement in advocacy for safe abortion via a range of different activities and partnerships, leading to incremental positive changes in safe and quality abortion care through the society's influence on policies, attitudes and knowledge. Building networks and working in partnerships at national and international levels has been a key element.

The project also continues to work with SAGO and the 20 country Community of Practice created previously and developed through partnership with other regional partners. A significant achievement in 2024 was the in-person meeting of this Community of Practice held in Togo in September 2024, bringing together over 50 health care providers including ObGyns, midwives and young professionals to discuss matters relating to safe abortion advocacy. The project also had a strong presence at national Congresses in both Togo and Cote d'Ivoire, bringing together representatives of FIGO member societies across Francophone Africa to continue discussions on safe abortion in the region.

The project also continues to work with FIGO's Safe Abortion Committee and contributes to raise FIGO's international profile on the topic of abortion/SRHR. This included representation during the virtual Global Safe Abortion Dialogue in July 2024.

Also included under this portfolio was a one year project with the member society in Zambia to implement WHO guidelines pertaining to self-managed abortion, funded through a collaboration with CHAI and CIFF. This project finished mid-2024 with a range of outputs that were shared via FIGO's website and other channels.

**Collaborate for Women: Abortion and Contraception Care Together (A4W ACCT)**

A new project was initiated in collaboration with the WHO towards the end of 2024. The C4W ACCT project aims to strengthen capacity and support for national uptake of competency-based education in family planning (FP) and comprehensive abortion care (CAC) across five countries in Africa and Asia. It also seeks to build inter-professional collaboration



Trustees' report

For the year ended 31 December 2024

---

among Ob-Gyns, midwives, and other key stakeholders to ensure sustainable improvements in women's health. Initially funded for a one-year period, the project is working with national member societies in Bangladesh, DRC, Mozambique, Nepal and Sierra Leone.

With funding starting in October, the main focus in 2024 was on-boarding these five societies, with work on the main project deliverables (Needs Assessments, Road maps and Curricula assessments) commencing from January 2025.

**Fistula Surgery Training Initiative (FSTI)**

Funders: Texas Children's Hospital (TCH), an anonymous foundation and Hamlin Fistula Australia

FIGO plays a crucial role in maternal and new-born health by addressing obstetric fistula, a life-shattering birth injury caused by unrelieved obstructed labour. It affects the most disadvantaged women in low-resource settings and leads to chronic leakage of urine and/or faecal matter. Without a trained, competent fistula surgeon to repair the injury, a woman with an obstetric fistula will be incontinent for the rest of her life, causing unimaginable suffering and stigmatisation, as well as calamitous social and economic consequences.

Obstetric fistula can be prevented by making quality maternal health services available for all, especially emergency caesarean sections (C-sections). Yet, tragically, the condition continues to devastate the lives of 50,000 to 100,000 women every year in 60 of the world's low-resource countries. This adds to the backlog of one to two million women still suffering with the condition, due to the lack of well-trained, competent fistula surgeons.

Recognising obstetric fistula as a neglected public health issue and to bridge the global treatment gap, in 2012, FIGO launched an ambitious training programme to greatly increase the number of fistula surgeons. The programme builds the capacities of 'FIGO Fellows' - trainee fistula surgeons from fistula-affected countries – starting with initial training in a FIGO Certified Training Centre and subsequent coaching sessions by FIGO Trainers.

The initiative has expanded substantially since its early days, and at 31 December 2024, there were 93 Fellows from 28 high-need countries in sub-Saharan Africa and Asia being trained as fistula surgeons, as well as multiple fistula care teams who have also received FIGO training. Eight new Fellows joined the Programme in 2024. Fifteen other established Fellows received coaching sessions with FIGO Trainers to enhance their fistula repair skills. Some of these sessions took place in Fellows' own facilities, and others in training centres. In addition, two more 'live on-line training sessions' were organised in 2024, making a total of 13 so far. Facilitated by two FIGO Trainers and focusing on a specific aspect of fistula surgery each time, these popular sessions allow direct discussion between the Fellows and trainers, and are always well attended.

Trustees' report

For the year ended 31 December 2024

---

The FSTI achieved notable milestones in 2024 including the following:

**1. Expert Surgical Workshop, Addis Ababa, February 2024**

The purpose of the workshop was to share ideas and discuss new, as well as less established approaches on how to treat ongoing urinary incontinence post vesicovaginal fistula repair, with the aim of reducing/curing the incontinence and thereby avoiding a urinary diversion when possible.

**2. Annual Expert Advisory Group (EAG) meeting in Eldoret, Kenya, August 2024**

The annual two days EAG meeting took place at FIGO Training Centre, Gynocare- Women's and Fistula Hospital in Eldoret, Kenya in August and provided the opportunity to discuss Fellow progress and multiple issues relating to the Training Initiative.

**3. Surgical Workshops, Eldoret, Kenya, August 2024**

Following the EAG meeting, the project team and the Trainers of the EAG stayed on to hold a three-day surgical workshop for Kenyan Fellows in collaboration with the Gynocare team. Working directly with the Trainers, and with three operating theatres running simultaneously, the Fellows were able to see new techniques in fistula repair surgery and to further develop their skills. Additionally, equipment supplier Tim Beacon from Medical Aid joined the workshop to review the FIGO fistula instrument sets used by the FIGO Training Initiative to continue modifying and improving the sets, according to surgeons' recommendations.

**4. New Fistula Training Centre**

In line with the growing initiative and the increasing need for more training places, conversations commenced to accredit a new training centre in northern Tanzania. At the end of 2024, an MoU was drawn up which is due to be signed in 2025.

**5. Publication of Good Practice Recommendations**

The paper "*FIGO good practice recommendations to standardize the assessment of outcomes following vesicovaginal fistula surgery*" was submitted to the International Journal of Gynecology and Obstetrics (IJGO) in late 2024 and has now been published as an open-access special article which will also be included in the IJGO's February 2025 edition. The project team is currently exploring options to have the article translated into French and Portuguese.

**6. Quarterly Fistula Newsletters**

Three FSTI Newsletters were compiled in 2024 and distributed worldwide to stakeholders of the FSTI and the fistula community. The fourth newsletter for 2024 was released in very early 2025.

**7. Programme Statistics at the end of 2024**

At the end of December 2024, there were 93 Fellows from 28 countries enrolled on the FSTI, who had collectively performed more than 24,000 fistula repairs worldwide, as well as thousands of associated procedures, including 4th degree perineal tears, ureteric re-implantations and ongoing incontinence procedures, thus transforming the lives of some of the most vulnerable and hardest to reach women on the planet.

Trustees' report

For the year ended 31 December 2024

---

**8. Funding**

After extensive efforts by the fistula team to fund raise for the FSTI in the past, in order to ensure its stability and longevity by having several funding partners, in 2024, the FSTI was receiving funds from the following three donors:

1. Texas Children's Hospital (TCH) - 2024 was year 5 of a 5 year contract
2. An anonymous foundation - 2024 was year 3 of a 3 year contract
3. Hamlin Fistula Australia - 2024 was year 2 of a 3 year contract

Discussions with TCH and the anonymous foundation took place in late 2024 and early 2025, to expend the funding for the FSTI beyond December 2024 with the following results:

1. Texas Children's Hospital (TCH). Funding was renewed for 2025 but instead of a multi-year contract, funding will now be renewed annually. For 2025, \$400,000 were secured.
2. An anonymous foundation. Funding was renewed in early 2025 and \$750,000 were awarded over three years.

**Accelerating Measurable Progress and Leveraging Investments for PostPartum Haemorrhage Impact (AMPLI-PPHI)**

FIGO is working in a consortium on a four year, UNITAID funded project, led by JHPIEGO and in partnership with PATH. Member Societies in four target countries, DRC, Guinea, Kenya and India, are working alongside their JHPIEGO and PATH counterparts to bring about an increase in the demand and adoption of three newly introduced drugs to tackle PPH treatment and management. This focusses on the use of TXA, Heat-stable Carbetocin and the self-administration of misoprostol. During 2024, the third year of the project, country teams have developed national networks of key stakeholders, working together to advocate for the safe introduction, training and implementation of these critical drugs into frontline practice. They have raised their voices through their societies, using national opportunities to build awareness and taking opportunities to build commitment to their adoption as best practice. The year saw the successful launch of 2 additional country teams, Zambia and Nigeria, who have joined the programme. All 6 Society teams have led the way in updating Emergency medicine lists, supporting the registration of supplies of the drugs as well as now developing appropriate pathways to their inclusion and wider adoption. Working alongside consortium partners, developing curriculums and implementing training in selected training facilities, they have united multi-stakeholder national networks to increase commitment to tackling PPH and opened pathways to ensure the drugs can be scaled up.

As a key element of creating this pathway to scale up through this project, 13 additional societies have been connected in. The development of the 'exchange hubs' linked to each of the target countries has allowed project learning, country experiences and lessons learnt to be shared and scaled up more quickly to a wider number of countries and allowed more women to receive the best possible care. FIGO member societies have been connected, and they are now developing strong hubs where they can exchange and support one another.

Trustees' report

For the year ended 31 December 2024

---

**The FIGO Leadership Development Initiative: Removing barriers to access and effective coverage of maternal healthcare (LDI:REACH)**

This grant was awarded by the Bill and Melinda Gates Foundation in October 2022 and commenced on November 1st 2022. It runs until October 31<sup>st</sup> 2025. It supports national Obstetric and Gynaecologic Societies in six countries in their efforts to improve maternal health outcomes and meet the UN's Sustainable Development Goal (SDG) 3, by addressing targeted clinical interventions and looking at the barriers to the effective coverage of those interventions, in terms of the implementation of best practices. The focus countries are Ethiopia, Kenya, Nigeria, Pakistan, India (Uttar Pradesh and Bihar regions) and Bangladesh.

The programme focuses on increasing the coverage of key maternal health clinical interventions, identifying the barriers to effective coverage of those interventions, locally, nationally and internationally and strengthening the professional society to address those barriers through four key approaches. These approaches focus on leadership empowerment, advocacy, gender equity and communication.

Identification of barriers is informed by a bespoke Barrier Assessment Tool (BAT), which is conducted at national, regional and facility levels, every 4–6 months, with the aim to assess the specific context for each clinical intervention. Barriers are prioritised and tracked using a Barrier Tracker and the BAT is then repeated to monitor progress and developments. Strengthening the leadership skills and voice of the health professionals, and having a better understanding of why a particular recommended practice is not widely adopted is the key to removing the barrier and improving the provision of quality care.

During 2024, country teams have undertaken 2 further BAT cycles, prioritised further key areas of focus to address those barriers and led training, developed job aids and updated national policies. A second 5 week leadership empowerment series was run by FIGO to continue to support professional society leadership skill development and a full year's data on the effective coverage of best practices was collected, analysed and utilised for further learning.

LDI:REACH allows physicians to assess barriers to care, improve gender diversity, educate and collaborate on guideline implementation, collaborate with health care professionals and lead facility changes so that staffing, equipment and medications are available and all women can receive the right care for every birth.

**Eliminating Cervical Cancer**

Four pilot projects were funded by FIGO from dormant funds that were re-designated early in 2021. These projects are located in India, Nigeria, Columbia and Nepal and of the total funding of £80,000, the remaining balance was £16,905 as at the end of 2024.

## Divisions and Committees

FIGO's scientific committees bring together global leaders in clinical practice, research, and education collaborating to drive forward our mission and strategic plan. FIGO's committees play a pivotal role in promoting education and research implementation, using evidence-based approaches to address key women's health challenges worldwide.

In December 2024 the Board of Trustees approved the President's proposal to establish five new FIGO committees and a new division—the Division of Well Woman Health Care. With this addition, FIGO now has a total of 21 scientific committees organized under four divisions. The committees are very active and produce regular webinars, publications, statements, and other key outputs such as e-learning courses and educational infographics. FIGO funds most expenses of committees from its unrestricted funds and seeks additional funding from donors for individual initiatives where appropriate.

## FIGO Trading Company

The Charity's wholly owned trading subsidiary, FIGO Trading Limited, operates commercial trading activities on behalf of the Charity, including organising and managing the biennial FIGO World Congress of Gynecology & Obstetrics, occasional regional events and publication of the official journal of FIGO, the 'International Journal of Gynecology and Obstetrics' (IJGO). The company made a profit of £60,554 during the year to 31 December 2024 (2023: £1,081,935). The company made a gift of £60,554 (2023: £1,081,935) to the Charity in accordance with its Memorandum of Association.

## The International Journal of Gynecology & Obstetrics (IJGO)

The International Journal of Gynecology & Obstetrics (IJGO) is the official scientific journal of FIGO. It publishes trusted, peer-reviewed original research, reviews and brief communications in all areas of obstetrics and gynaecology, with focus on globally relevant aspects of care and under the auspices of an international Editorial Board. Publications during 2024 included 15 papers authored by FIGO's expert committees, which have all seen strong levels of readership and engagement.

The number of submissions to the journal continues to grow – up by 23% in 2024 compared with 2023 – as does the number of articles accepted and published – up by 12% in 2024 compared with 2023.

The Impact Factor (IF) represents how many times papers published in IJGO were cited in indexed scientific journals during a particular year. The 2023 IF (announced in June 2024) saw a moderate drop to 2.6, down from 3.8 (2022), in a pattern consistent with most journals in the field post-Covid.

Trustees' report

For the year ended 31 December 2024

---

Many articles are accessed by academic institutional subscribers, and a number of free access and open access articles are downloaded by a wider readership. Uptake of open access by authors seen a moderate percentage decline in 2024 to 29% (from 38% in 2023), although due to the overall increase in total number of articles published, open access has remained an area of revenue growth (increased open access revenue in part offsets the continuing steady decline in subscriptions revenue). Total readership of IJGO increased by 15.6% in 2024.

**Education, Communication and Advocacy Committee (ECAC)**

This committee is chaired by the Vice President. The committee's aim is to leverage the experience and expertise of the Regional Trustees to identify the specific needs of each FIGO region. The overarching role of the committee is to provide guidance that supports FIGO to develop appropriate region-specific educational and training activities to address these needs, including timely advocacy efforts as and when the opportunity arises. ECAC oversees the FIGO global webinar series and will guide future educational efforts, liaising with divisions and committees and FIGO HQ.

**Financial review**

The principal funding sources of the group were contribution income from Society Member associations of £441,280 (2023: £420,586), Journal income of £810,751 (2023: £847,632), restricted grants of £2,165,873 (2023: £2,836,221) .

The group has incurred expenditure of £2,706,472 (2023: £3,614,893) in respect of restricted fund projects during the year as shown in Note 18 to the accounts.

The group's unrestricted expenditure for 2024 was £2,511,251 (2023: £5,486,868). The group's unrestricted surplus (before movements on investments and foreign exchange) for 2024 was a deficit of £1,048,993 (2023: surplus of £520,420) in this non-congress year.

FIGO registered gains of £85,148 (2023: gains of £277,560) on its investment holdings. Income received from investments in 2024 amounted to £220,267 (2023: £280,442).

Negative foreign exchange translation differences totalled £31,237 (2023: losses of £302,035).

The group's balance sheet is strong with a closing total unrestricted reserves of £6,114,205 (2023: £7,109,287) and healthy liquidity provided by cash balances of £3,707,856 (2023: £4,911,687) and investment holdings of £3,188,007 (2023: £3,102,859). Total funds carried forward as at 31 December 2023 were £8,895,872 (2023: £10,431,546).

Trustees' report

For the year ended 31 December 2024

---

FIGO participates in a multi-employer pension scheme. At 31 December 2024, FIGO's share in the plan's surplus amounted to £45,000 (2023: surplus of £70,000), however this has been capped at £nil as FIGO is unable to access the surplus to reduce contributions or obtain a refund. FIGO recorded an actuarial gain of £nil (2023: £nil) during the financial year. Further details on the pension scheme are provided in note 20 to the accounts.

The Charity adopts a prudent financial policy that aims to ensure that all activities undertaken are efficiently managed in accordance with approved budgets and in accordance with good practice. All expenditure is monitored and payments processed through a system that endeavours to ensure that any possibility of error is minimised.

## Principal risks and uncertainties

The trustees perform a review to identify the major risks to which the Charity is exposed on an annual basis and have established systems and procedures to mitigate these risks. These risks include the possibility of adverse currency fluctuations, a reduction in third party grants and donations and an unexpected downturn in attendance at the organisation's biennial Congress.

An Audit and Risk Committee was created in October 2021 that functioned separately from the Finance Committee that dealt with the overall management of the Finances. In December 2023 the Board of Trustees asked the Executive to look at combining the Finance Committee with the Audit and Risk Committee to produce a single committee with oversight of all Finance, Audit and Risk related matters. This was formally established in 2024.

The risks identified above are managed through a diverse investment strategy, ensuring a professional and effective relationship with the donor community and consideration of alternative revenue streams. The risks associated with the biennial Congress are managed via the Congress Organising Committee which meets several times during the planning period to ensure the successful management of the event (including mitigation of associated risks).

FIGO maintains several foreign currency bank accounts for activities taking place internationally which are funded from donor grants. Expenditure incurred overseas is paid from these foreign currency bank accounts, thereby minimising any currency exposure.

The group's principal financial assets are bank balances, trade debtors and investments.

The group's credit risk is primarily attributable to its trade debtors. Trade debtors are included in the financial statements net of provision for doubtful debts. There is no significant concentration of credit risks, with exposure spread over many parties. A regular review is performed of available funds to settle debts as they fall due and active management of the trade debtors and creditors balances to ensure sufficient working capital is available to the group.

Trustees' report

For the year ended 31 December 2024

---

## Fundraising

FIGO has not engaged in public fundraising and has not used professional fundraisers or commercial participators. The charity nevertheless is committed to observing all relevant fundraising regulations and codes. There was no non-compliance of these regulations and codes and the charity received no complaints relating to its fundraising practice.

FIGO HQ has been receiving advice from consultants with expertise in writing grant proposals in order to identify new sources of funding. Several major donors are moving to a new model where they donate money directly to the region and countries involved in the projects.

## Reserves policy and going concern

The organisation aims to retain sufficient free reserves to ensure the continued efficient running of the core elements of the Charity.

The level of free reserves at any time will be affected by the proximity of the FIGO World Congress of Gynecology and Obstetrics, which now takes place every two years. Profits from the Congress are used to replenish the level of free reserves, to be drawn on to fund core activities of the charity in years when a Congress does not occur.

The trustees consider that a baseline of free reserves should be maintained to ensure the core functions can continue for two years even in the event that a Congress is not profitable or has to be cancelled and uninsurable losses arise.

Therefore, the level of reserves will fluctuate year on year but may represent up to two years' core operating costs (including Payroll, Rent and Information Technology). Based on current and planned levels of expenditure the level of reserves should vary between £2.0m and £4.0m, reducing as a Congress year approaches and depending on the result arising from the Congress. The level of financial reserves is reviewed continually by the Chief Executive and annually by the wider Trustee Board as well as by the organisation's Audit & Finance Committee.

At 31 December 2024, the group has reserves that are freely available for expending on charitable purposes of £5,108,590 (2023: £6,063,225). This has been calculated as General funds, equating to total reserves, excluding restricted funds, Pensions reserve and Designated funds, which includes the value of tangible fixed assets held for use by the charity. The reserves at 31 December 2024 are above the level required by the reserves policy of £2.2m (i.e. two year's payroll and information technology costs).



## Plans for the future

The Charity aims to continue its charitable activities for the promotion of the health and well-being of women and their children by improving the practice of obstetrics and gynaecology. As part of supporting an enabling environment for this focus, we will continue to champion women's and girls' reproductive and health rights more widely, recognising the increasing attacks on these rights in many countries and the adverse impact of funding cuts.

In December 2023 the Board of Trustees endorsed a plan to review the efficiency and effectiveness of each area of FIGO's current operation and to increase collaboration and impact across the organisation. This review, and a programme of work to deliver change informed by it, is a core focus for FIGO in 2025 – and beyond.

In 2024 we undertook reviews of several parts of our operation. These included finance systems and capability, IT infrastructure, membership services, projects and programmes in LMICs, our publishing contract for the International Journal of Obstetrics and Gynaecology and decision-making and cost-control for FIGO Congress. During 2025 we will review our communications and advocacy systems and capability, and potential future models for our education work.

In 2025 we will invest to strengthen our business development capacity with an emphasis on securing income to fund and expand our programmes and projects with our member societies and other partners in LMICs. We will also strengthen our capacity in advocacy and continue to strengthen collaborative partnerships with organisations whose goals and values align with FIGO's strategic priorities.

Over this period, we will continue to increase the capacity of our member societies to help strengthen their voice nationally and support their role in disseminating knowledge and expertise from FIGO's Scientific Committees. We will continue our working relationship as Non-State Actors in Official Relations with the World Health Organisation, with a particular focus on reducing Post-Partum Haemorrhage, eliminating cervical cancer, and supporting access to family planning and comprehensive abortion care. In October 2025 we will stage our bi-annual World Congress in Cape Town, South Africa.

## Structure, governance and management

The organisation is a charitable company limited by guarantee, incorporated on 4<sup>th</sup> July 2005 and registered as a charity on 14<sup>th</sup> March 2006.

The company was established under a memorandum of association, which established the objects and powers of the charitable company and is governed under its articles of association. During 2019 the Articles of Association were rewritten and adopted at an Extraordinary General Meeting held in Manila, Philippines on Tuesday 12<sup>th</sup> November 2019. The Articles of

**Trustees' report**

**For the year ended 31 December 2024**

---

Association were further amended by special resolution at a General Meeting of the Company held on Sunday 6th December 2020.

All trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 6 to the accounts.

## **Appointment of trustees**

The International Federation of Gynecology and Obstetrics has a single management body, the Board of Trustees, elected by its Society Members at each General Assembly meeting.

## **Trustee induction and training**

New trustees receive detailed guidance on the organisational and decision-making structure of the organisation as part of their first meeting together with information on their legal and moral obligations as trustees of the charity. Trustees are also given a Trustee Handbook which outlines the way in which FIGO operates and includes detailed guidance on their role as a Trustee, their statutory duties and their responsibilities. In addition, they are required to sign a Code of Conduct.

Trustees regularly consider the latest guidance from the Charity Commission and other relevant bodies on good practice and undertake such training as is recommended to them.

## **Related parties and relationships with other organisations**

The trustees of the charity give their time freely and receive no remuneration other than reimbursement of reasonable out-of-pocket expenses.

The Charity's wholly owned subsidiary, FIGO Trading Limited, was established to operate the commercial trading activities of the Charity and in each year of operation FIGO Trading Limited gifts its profits to the Charity.

The Charity has a close relationship with The FIGO Charitable Foundation, a corporation incorporated in the State of Illinois, USA. The Corporation was established for charitable, educational and scientific purposes and during the year to 31 December 2023 its activity has been to raise funds for such purposes on behalf of the Charity. The FIGO charitable foundation receives Donor gifts denominated in shares and sells those shares for cash, which is then remitted to the Charity. During the year, £nil (2023: nil) was remitted for the project relating to Advocating Safe Abortion.

The Charity also has a relationship with the International Federation of Gynecology and Obstetrics, which was established in Switzerland in accordance with Section 60 of the Swiss Civil Code et seq. On 1 January 2008, the Swiss organisation transferred its assets and activities

## Trustees' report

For the year ended 31 December 2024

---

to the Charity via a deed of gift. The Swiss organisation ceased all activity at that date and is now dormant.

## Remuneration policy for key management personnel

The pay and remuneration of the charity's key management personnel is established through job evaluation, sector benchmarking, availability of funding, recruitment advertising, individuals' skills, knowledge & experience and relevant salary surveys comparison. The Chief Executive, together with Senior Managers, will review budget availability for all appointments. The President of FIGO reviews the remuneration of the Chief Executive and reports on this to the Board of Trustees.

## Statement of responsibilities of the trustees

The trustees (who are also directors of the International Federation of Gynecology & Obstetrics for the purposes of company law) are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP
- Make judgements and estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information

**Trustees' report**

**For the year ended 31 December 2024**

---

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The trustees' annual report, prepared in accordance with small company exemptions, has been approved by the trustees on 16 September 2025 and signed on their behalf by:

Dr Anne Beatrice Kihara  
President

## Opinion

We have audited the financial statements of International Federation of Gynecology and Obstetrics (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the group's and of the parent charitable company's affairs as at 31 December 2024 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice
- Have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011

## Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the group financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

## **Other Information**

The other information comprises the information included in the trustees' annual report other than the group financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the group financial statements does not cover the other information, and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the group financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the group financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements
- The trustees' annual report has been prepared in accordance with applicable legal requirements

## **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Act 2011 requires us to report to you if, in our opinion:

- Adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- The parent charitable company financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' annual report and from the requirement to prepare a strategic report.

## **Responsibilities of trustees**

As explained more fully in the statement of trustees' responsibilities set out in the trustees' annual report, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

## **Auditor's responsibilities for the audit of the financial statements**

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

## **Capability of the audit in detecting irregularities**

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- We enquired of management and trustees, which included obtaining and reviewing supporting documentation, concerning the group's policies and procedures relating to:
  - Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;
  - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;

## Independent auditor's report

To the members of

### International Federation of Gynecology and Obstetrics

---

- The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
- We inspected the minutes of meetings of those charged with governance.
- We obtained an understanding of the legal and regulatory framework that the group operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the group from our professional and sector experience.
- We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit.
- We reviewed any reports made to regulators.
- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.
- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.
- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

## Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose.



## **Independent auditor's report**

**To the members of**

**International Federation of Gynecology and Obstetrics**

---

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Joanna Pittman (Senior statutory auditor)

22 September 2025

for and on behalf of Sayer Vincent LLP, Statutory Auditor

110 Golden Lane, LONDON, EC1Y 0TG

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006

International Federation of Gynecology and Obstetrics

Consolidated statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2024

			2024			2023	
	Note	Unrestricted £	Restricted £	Total £	Unrestricted £	Restricted £	Total £
Income from:							
Donations and legacies		7,486	-	7,486	46,988	-	46,988
Charitable activities							
Membership		441,280	-	441,280	420,586	-	420,586
Projects		-	2,165,873	2,165,873	-	2,836,221	2,836,221
World Congress		(17,525)	-	(17,525)	4,411,640	-	4,411,640
Journal		810,751	-	810,751	847,632	-	847,632
Investments	2	220,267	-	220,267	280,442	-	280,442
<b>Total Income</b>		<b>1,462,259</b>	<b>2,165,873</b>	<b>3,628,132</b>	<b>6,007,288</b>	<b>2,836,221</b>	<b>8,843,509</b>
Expenditure on:							
Raising funds		-	-	-	-	-	-
Charitable activities		2,511,252	2,706,472	5,217,724	5,486,868	3,614,893	9,101,761
<b>Total expenditure</b>	<b>3a</b>	<b>2,511,252</b>	<b>2,706,472</b>	<b>5,217,724</b>	<b>5,486,868</b>	<b>3,614,893</b>	<b>9,101,761</b>
Net income / (expenditure) before net gains / (losses) on investments		(1,048,993)	(540,599)	(1,589,592)	520,420	(778,672)	(258,252)
Net gains / (losses on investments)	11	85,148	-	85,148	277,560	-	277,560
<b>Net income / (expenditure) for the year</b>	<b>5</b>	<b>(963,845)</b>	<b>(540,599)</b>	<b>(1,504,444)</b>	<b>797,980</b>	<b>(778,672)</b>	<b>19,308</b>
<b>Transfers between funds</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income / (expenditure) before other recognised gains and losses</b>		<b>(963,845)</b>	<b>(540,599)</b>	<b>(1,504,444)</b>	<b>797,980</b>	<b>(778,672)</b>	<b>19,308</b>
Other gains / (losses) on foreign exchange		(31,237)	-	(31,237)	(302,035)	-	(302,035)
<b>Net movement in funds</b>		<b>(995,082)</b>	<b>(540,599)</b>	<b>(1,535,681)</b>	<b>495,945</b>	<b>(778,672)</b>	<b>(282,727)</b>
<b>Reconciliation of funds:</b>							
<b>Total funds brought forward</b>		<b>7,109,287</b>	<b>3,322,259</b>	<b>10,431,546</b>	<b>6,613,342</b>	<b>4,100,931</b>	<b>10,714,273</b>
<b>Total funds carried forward</b>		<b>6,114,205</b>	<b>2,781,660</b>	<b>8,895,865</b>	<b>7,109,287</b>	<b>3,322,259</b>	<b>10,431,546</b>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements

## Balance sheets

Company no. 05498067

As at 31 December 2024

		The group		The charity	
		2024	2023	2024	2023
	Note	£	£	£	£
<b>Fixed assets:</b>					
Tangible assets	10	1,005,617	1,046,062	1,004,630	1,044,734
Investments	11	3,188,007	3,102,859	3,188,007	3,102,859
		<u>4,193,624</u>	<u>4,148,921</u>	<u>4,192,637</u>	<u>4,147,593</u>
<b>Current assets:</b>					
Debtors	14	1,414,916	2,159,001	2,181,821	2,903,419
Cash at bank and in hand		<u>3,707,856</u>	<u>4,911,687</u>	<u>2,887,381</u>	<u>4,059,430</u>
		<u>5,122,772</u>	<u>7,070,688</u>	<u>5,069,202</u>	<u>6,962,849</u>
<b>Liabilities</b>					
Creditors: amounts falling due within one year	15	<u>(420,531)</u>	<u>(788,063)</u>	<u>(365,974)</u>	<u>(678,896)</u>
<b>Net current assets</b>		<u><b>4,702,241</b></u>	<u><b>6,282,625</b></u>	<u><b>4,703,228</b></u>	<u><b>6,283,953</b></u>
<b>Net assets excluding pension scheme liability</b>		<b>8,895,865</b>	<b>10,431,546</b>	<b>8,895,865</b>	<b>10,431,546</b>
<b>Defined benefit pension scheme surplus / (liability)</b>	21	-	-	-	-
<b>Total net assets</b>	17a	<u><b>8,895,865</b></u>	<u><b>10,431,546</b></u>	<u><b>8,895,865</b></u>	<u><b>10,431,546</b></u>
<b>Funds:</b>					
Restricted income funds:		2,781,660	3,322,259	2,781,660	3,322,259
Unrestricted income funds:					
Designated funds		1,005,617	1,046,062	1,004,630	1,044,734
General funds		5,108,588	6,063,225	5,109,575	6,064,553
Pension reserve		<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total unrestricted funds		<u>6,114,205</u>	<u>7,109,287</u>	<u>6,114,205</u>	<u>7,109,287</u>
<b>Total funds</b>		<u><b>8,895,865</b></u>	<u><b>10,431,546</b></u>	<u><b>8,895,865</b></u>	<u><b>10,431,546</b></u>

Approved by the trustees on 16th September 2025 and signed on their behalf by

Dr Anne Kihara  
PresidentDr Shantha Kumari  
Treasurer

## Consolidated statement of cash flows

For the year ended 31 December 2024

	Note	2024		2023	
		£	£	£	£
<b>Cash flows from operating activities</b>					
Net income/expenditure for the reporting period (as per the statement of financial activities)		(1,535,681)		(282,727)	
Revaluation due to exchange rate movements		31,237		302,035	
Depreciation charges		47,849		49,275	
(Gains)/losses on investments		(85,148)		(277,560)	
Dividends, interest and rent from investments		(220,267)		(280,442)	
Decrease/(increase) in debtors		744,085		(1,649,376)	
Decrease in creditors		(367,533)		168,591	
(Decrease) in pension liability		-		-	
Net cash provided by (used in) operating activities			(1,385,459)		(1,970,204)
<b>Cash flows from investing activities:</b>					
Dividends, interest and rent from investments		220,267		280,442	
Purchase of fixed assets		(7,400)		(12,114)	
Proceeds from sale of investments		-		-	
Purchase of investments		-		(741)	
Net cash (used in) / provided by investing activities			212,867		267,587
Change in cash and cash equivalents in the year			(1,172,592)		(1,702,617)
Cash and cash equivalents at the beginning of the year			4,911,687		6,916,339
Change in cash and cash equivalents due to exchange rate movements			(31,237)		(302,035)
Cash and cash equivalents at the end of the year			<u>3,707,856</u>		<u>4,911,687</u>

**1 Accounting policies**

**a) Statutory information**

International Federation of Gynecology and Obstetrics is a charitable company limited by guarantee and is incorporated in the United Kingdom.

The registered office address is Suite 3, Waterloo Court, 10 Theed Street, London, SE1 8ST.

**b) Basis of preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

These financial statements consolidate the results of the charitable company and its wholly-owned subsidiary FIGO Trading Limited (company registration number 05895905) on a line by line basis. Transactions and balances between the charitable company and its subsidiary have been eliminated from the consolidated financial statements. Balances between the two companies are disclosed in the notes of the charitable company's balance sheet. A separate statement of financial activities, or income and expenditure account, for the charitable company itself is not presented because the charitable company has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006.

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

**c) Public benefit entity**

The charitable company meets the definition of a public benefit entity under FRS 102.

**d) Going concern**

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern. It is expected that in a non-congress year, FIGO may operate with a small unrestricted deficit and also has sufficient free reserves to ensure continued efficient running of the core elements of the Charity.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

**e) Income**

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

FIGO Society Member Affiliate Membership fees are accounted for on an accruals basis.

Income from royalties and editorial support (IIGO) is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Congress income is recognised as income in the year that the Congress takes place. Congress income received in advance is deferred until the year of the Congress.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

**f) Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

**g) Fund accounting**

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

1 Accounting policies (continued)

h) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

- Costs of raising funds relate to the costs associated with attracting donations and investment management costs.
  - Expenditure on charitable activities includes the costs of delivering its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
  - Other expenditure represents those items not falling into any other heading
  - Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff costs, finance costs and governance costs that support the charity's activities. These costs have been allocated to expenditure on charitable activities. Costs relating to a particular activity are allocated directly and others are apportioned
- Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

i) Grants payable

Grants payable are made to third parties in furtherance of the charity's objects. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and that any condition attaching to the grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

j) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £1,500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use. Major components are treated as a separate asset where they have significantly different patterns of consumption of economic benefits and are depreciated separately over its useful life.

Where fixed assets have been revalued, any excess between the revalued amount and the historic cost of the asset will be shown as a revaluation reserve in the balance sheet.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

- |                         |   |
|-------------------------|---|
| Long leasehold property | Not depreciated as recoverable amount deemed to exceed carrying value |
| Leasehold improvements  | 15 years - straight line  |
| Office equipment        | 25% - reducing balance  |
| Computer equipment      | 25% - straight line   |

k) Listed investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. Any change in fair value will be recognised in the statement of financial activities. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading "Net gains/(losses) on investments" in the statement of financial activities. The charity does not acquire put options, derivatives or other complex financial instruments.

l) Investments in subsidiaries

Investments in subsidiaries are at cost.

m) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

n) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

o) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

p) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Notes to the financial statements

For the year ended 31 December 2024

1 Accounting policies (continued)

q) Pensions

FIGO participates in the Royal College of Obstetricians and Gynaecologists Pension Scheme (the scheme) a UK registered trust-based pension scheme that provides defined benefits linked to members final pensionable salaries and their period of service as a member of the scheme. The scheme closed to future accrual of defined benefits with effect from 31 December 2014. The trustees are responsible for running the scheme in accordance with the scheme's Trust Deed and Rules, which sets out their powers. The Trustees of the scheme are required to act in the best interests of the beneficiaries of the scheme.

There are three categories of pension scheme members:

- In-service deferred members: currently employed by a participating employer. These members' pensions are based on their final pensionable salaries at retirement or earlier date of leaving the scheme.
- Deferred members: those not currently employed by a participating employer and whose pension has not yet started.
- Pensioner members: former members in receipt of pension

The charity also participates in a defined contribution pension scheme for the employees who joined the charity after 2003. The assets of the scheme are held separate from those of the charity. The cost of pension contributions for the defined contribution scheme are charged to the Statement of Financial Activities as they become payable.

r) Foreign currencies

Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are included as support costs.

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Exchange differences on these conversions are included in other gains and losses.

2 Income from investments

	2024	2023
	Total	Total
	£	£
Investment income	90,509	81,881
Bank interest	129,758	198,561
	<u>220,267</u>	<u>280,442</u>

All income from investments is unrestricted

Notes to the financial statements

For the year ended 31 December 2024

3a Analysis of expenditure (current year)

	Raising funds £	Charitable activities £	Governance costs £	Support costs £	2024 Total £	2023 Total £
Staff costs (Note 6)	-	786,443	-	1,825,418	<b>2,611,861</b>	2,342,853
Project costs	-	365,998	-	-	<b>365,998</b>	918,802
Grant making (Note 4)	-	1,149,349	-	-	<b>1,149,349</b>	1,397,753
Committees	-	20,159	-	-	<b>20,159</b>	22,342
Finance costs	-	-	-	121,779	<b>121,779</b>	186,308
Journal	-	123,826	-	-	<b>123,826</b>	113,778
Congress	-	70,368	-	-	<b>70,368</b>	3,583,118
Office costs	-	-	-	138,130	<b>138,130</b>	68,220
Staff training and development	-	-	-	19,163	<b>19,163</b>	14,657
IT costs	-	-	-	151,580	<b>151,580</b>	46,934
Audit and accountancy	-	-	34,450	-	<b>34,450</b>	21,824
Legal and professional	-	-	-	84,170	<b>84,170</b>	106,291
Recruitment fees	-	-	-	32,414	<b>32,414</b>	65,891
Official representation	-	-	-	136,507	<b>136,507</b>	26,136
Communication costs	-	-	-	110,120	<b>110,121</b>	137,579
Depreciation	-	-	-	47,850	<b>47,849</b>	49,275
Overhead recharge	-	-	-	-	<b>-</b>	-
	-	2,516,143	34,450	2,667,131	<b>5,217,724</b>	9,101,761



## Notes to the financial statements

For the year ended 31 December 2024

## 3a Analysis of expenditure (prior year)

	Raising funds £	Charitable activities £	Governance costs £	Support costs £	2023 Total £
Staff costs (Note 6)	-	1,034,310	-	1,308,543	2,342,853
Project costs	-	918,802	-	-	918,802
Grant making (Note 4)	-	1,397,753	-	-	1,397,753
Committees	-	22,342	-	-	22,342
Finance costs	-	-	-	186,308	186,308
Journal	-	113,778	-	-	113,778
Congress	-	3,583,118	-	-	3,583,118
Office costs	-	-	-	68,220	68,220
Staff training and development	-	-	-	14,657	14,657
IT costs	-	-	-	46,934	46,934
Audit and accountancy	-	-	21,824	-	21,824
Legal and professional	-	-	-	106,291	106,291
Recruitment fees	-	-	-	65,891	65,891
Official representation	-	-	-	26,136	26,136
Communication costs	-	-	-	137,579	137,579
Depreciation	-	-	-	49,275	49,275
	-	7,070,103	21,824	2,009,834	9,101,761
Support costs	-	2,009,834	-	(2,009,834)	-
Governance costs	-	21,824	(21,824)	-	-
<b>Total expenditure 2023</b>	<b>-</b>	<b>9,101,761</b>	<b>-</b>	<b>-</b>	<b>9,101,761</b>

## Notes to the financial statements

For the year ended 31 December 2024

## 4 Grant making

	2024 £	2023 £
<b>Accelerating Measurable Progress and Leveraging Investments for PPH Impact (AMPLI-PPHI)</b>		
Federation Obstetrics & Gynaecological Societies India	56,230	38,158
Société Guinéenne de Gynécologie-Obstétrique	51,570	27,717
Kenya Obstetrical and Gynaecological Society (KOGS)	56,963	34,943
The Société Congolaise de Gynécologie Obstétrique	19,922	65,698
Society of Gynaecology & Obstetrics of Nigeria	31,158	-
Zambia Association of Gynaecologists & Obstetricians	32,944	-
	<b>248,787</b>	<b>166,516</b>
<b>Advocating for Safe Abortion (ASA)</b>		
National College of Obstetricians Gynecologists of Benin (CNGOB)	79,500	95,760
Société de Gynécologues et Obstétriciens du Burkina (SOGOB)	78,386	85,022
Society of Gynecologists and Obstetricians of Cameroon (SOGOC)	111,991	80,184
Société de Gynécologie et d'Obstétrique de Côte d'Ivoire (SOGOCI)	-	80,346
Kenya Obstetrical and Gynaecological Society (KOGS)	-	24,879
Société Malienne de Gynécologie Obstétrique (SOMAGO)	-	80,257
Associação Moçambicana de Obstetras e Ginecologistas (AMOG)	-	25,567
Sociedad Panamenã de Obstetricia y Ginecología (SPOG)	-	-
Sociedad Peruana de Obstetricia y Ginecología (SPOG)	-	-
Rwanda Society of Obstetricians and Gynecologists (RSOG)	-	-
Association of Obstetricians and Gynaecologists of Uganda (AOGU)	-	24,877
Zambia Association of Gynaecologists & Obstetricians (ZAGO)	436	200,896
	<b>270,313</b>	<b>697,788</b>
<b>Leadership Development Initiative (LDI)</b>		
Bangladesh Obstetrical & Gyn Soc SAFOG	74,626	53,020
Ethiopian Society of Obstetricians & Gynecologists (ESOG)	85,626	110,804
Kenya Obstetrical Gynaecological Society	112,181	105,744
Society of Gynaecology and Obstetrics of Nigeria (SOGON)	68,132	113,754
Federation of Obstetric & Gynaecological Societies of India	78,355	92,799
Society of Obstetricians & Gynaecologists of Pakistan	82,051	57,328
	<b>500,971</b>	<b>533,449</b>
<b>Merck - Elimination of Cervical Cancer: Pilot Project</b>		
End Cervical Cancer Nigeria Initiative	10,000	-
Federación Colombiana de Obstetricia y Ginecología (FECOLSOG)	10,000	-
	<b>20,000</b>	<b>-</b>

Notes to the financial statements

For the year ended 31 December 2024

4 Grant making (continued)

**WHO project - Abortion and Contraception Care Together**

The Association of Gynaecologists and Obstetricians of Mozambique (AMOG)	25,156	-
The Obstetrical and Gynaecological Society of Bangladesh (OGSB)	14,360	-
La Société Congolaise de Gynécologie et d'Obstétrique / the Congolese Society of Gynecology and Obstetrics (SCG)	26,933	-
The Nepal Society of Obstetricians and Gynaecologists (NESOG)	14,728	-
The Sierra Leone Association of Gynaecologists and Obstetricians (SLAGO)	28,101	-
	<b>109,278</b>	-
	-	-
<b>Total</b>	<b>1,149,349</b>	<b>1,397,753</b>
	-	-

All grants in both periods were to institutions

5 Net income / (expenditure) for the year

This is stated after charging / (crediting):

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Depreciation	47,849	49,275
Auditors remuneration (excluding VAT):	-	-
VAT and Corporation Tax services	-	1,170
Audit	34,450	20,000
Foreign exchange gains or losses	31,237	6,784

Notes to the financial statements

For the year ended 31 December 2024

**6 Analysis of staff costs, trustee remuneration and expenses and the cost of key management personnel**

Staff costs were as follows:

	2024	2023
	£	£
Salaries and wages	2,009,890	1,916,561
Consultancy costs	-	624
Group Life Assurance & Income Protection	21,021	21,879
Redundancy and termination costs	83,398	33,103
Social security costs	292,090	220,875
Employer's contribution to pension schemes	205,461	149,811
	<b>2,611,859</b>	<b>2,342,853</b>

The redundancy and termination costs were settled and paid at the balance sheet date.

The following number of employees received employee benefits in excess of £60,000 (excluding employer pension costs and employer's national insurance) during the year between:

	2024	2023
	No.	No.
£60,000 - £69,999	2	2
£70,000 - £79,999	3	1
£80,000 - £89,999	-	3
£90,000 - £99,999	1	-
£110,000 - £130,000	1	-
£140,000 - £150,000	-	-
£150,000 - £160,000	-	1
£160,000 - £170,000	-	-
£170,000 - £180,000	-	-
£180,000 - £190,000	-	-
£190,000 - £200,000	1	-

The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £957,974 (2023: £771,273).

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £123,842 incurred by: 10 members, (2023: £100,605 incurred by : 12) members.

**7 Staff numbers**

The average number of employees (head count based on number of staff employed) during the year was 39 (2023: 38)

**8 Related party transactions**

There are no related party transactions to disclose for 2024 (2023: none).

**9 Taxation**

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes. The charity's trading subsidiary FIGO Trading Limited distributes available profits under Gift Aid to the parent charity. Its charge to corporation tax in the year was £Nil (2022: £Nil)

Notes to the financial statements

For the year ended 31 December 2024

**10 Tangible fixed assets**

<b>The group</b>	Long leasehold property £	Leasehold improvement £	Computer equipment £	Office equipment £	<b>Total £</b>
<b>Cost</b>					
At the start of the year	778,384	250,184	79,800	225,923	<b>1,334,291</b>
Additions in year	-	-	-	7,400	<b>7,400</b>
At the end of the year	<u>778,384</u>	<u>250,184</u>	<u>79,800</u>	<u>233,323</u>	<b><u>1,341,691</u></b>
<b>Depreciation</b>					
At the start of the year	-	104,243	28,146	155,836	<b>288,225</b>
Charge for the year	-	16,679	13,761	17,409	<b>47,849</b>
At the end of the year	<u>-</u>	<u>120,922</u>	<u>41,907</u>	<u>173,245</u>	<b><u>336,074</u></b>
Net book value at the end of the year	<u>778,384</u>	<u>129,262</u>	<u>37,893</u>	<u>60,078</u>	<b><u>1,005,617</u></b>
At the start of the year	<u>778,384</u>	<u>145,940</u>	<u>51,654</u>	<u>70,084</u>	<b><u>1,046,062</u></b>

## Notes to the financial statements

For the year ended 31 December 2024

**10 Tangible fixed assets (continued)**

<b>The charity</b>	Long leasehold property £	Leasehold improvement £	Computer equipment £	Office equipment £	<b>Total £</b>
<b>Cost</b>					
At the start of the year	778,384	250,184	69,799	199,893	<b>1,298,260</b>
Additions in year	-	-	-	7,400	<b>7,400</b>
At the end of the year	<u>778,384</u>	<u>250,184</u>	<u>69,799</u>	<u>207,293</u>	<b><u>1,305,660</u></b>
<b>Depreciation</b>					
At the start of the year	-	104,243	17,915	131,367	<b>253,525</b>
Charge for the year	-	16,679	13,535	17,291	<b>47,505</b>
At the end of the year	<u>-</u>	<u>120,922</u>	<u>31,450</u>	<u>148,658</u>	<b><u>301,030</u></b>
Net book value at the end of the year	<u>778,384</u>	<u>129,262</u>	<u>38,349</u>	<u>58,635</u>	<b><u>1,004,630</u></b>
At the start of the year	<u>778,384</u>	<u>145,941</u>	<u>51,884</u>	<u>68,526</u>	<b><u>1,044,735</u></b>

The lease on the long leasehold property expires in 2990. This property is not depreciated as the recoverable amount is deemed to exceed the carrying value.

All of the above assets are used for charitable purposes.

Notes to the financial statements

For the year ended 31 December 2024

11 Listed investments

	The group		The charity	
	2024	2023	2024	2023
	£	£	£	£
Fair value at the start of the year	3,102,859	2,824,558	3,102,859	2,824,558
Additions at cost	-	741	-	741
Disposal proceeds	-	-	-	-
Net gain/(loss) on change in fair value	85,148	277,560	85,148	277,560
Fair value at the end of the year	<b>3,188,007</b>	<b>3,102,859</b>	<b>3,188,007</b>	<b>3,102,859</b>

Investments comprise:

	The group		The charity	
	2024	2023	2024	2023
	£	£	£	£
<b>Listed</b>				
UK equities	-	-	-	-
Other equities	-	-	-	-
Other investment	-	-	-	-
CCLA Investment: COIF Charities Ethical Investment Fund	3,188,001	3,102,853	3,188,001	3,102,853
<b>Unlisted</b>				
Investments in subsidiaries registered in the UK	6	6	6	6
	<b>3,188,007</b>	<b>3,102,859</b>	<b>3,188,007</b>	<b>3,102,859</b>



Notes to the financial statements

For the year ended 31 December 2024

## 12 Subsidiary undertakings

The charitable company owns the whole of the issued ordinary share capital of FIGO Trading Limited, a company registered in England. The subsidiary is used for commercial activities, including the organisation of the Biennial Congress and publication of the International Journal. All activities have been consolidated on a line by line basis in the statement of financial activities. Available profits are gift aided to the charitable company. Dr Shantha Kumari Sekaran, Trustee and Frances Longley, CEO, are also directors of the subsidiary. A summary of the results of the subsidiary is shown below:

	2024	2023
	£	£
Turnover	804,837	5,274,261
Cost of sales	(702,725)	(3,696,896)
Gross profit	102,112	1,577,365
Administrative expenses	(41,558)	(495,430)
Operating profit before taxation	60,554	1,081,935
Taxation	-	-
Profit on ordinary activities	60,554	1,081,935
<b>Retained earnings</b>		
Retained earnings brought forward	-	-
Profit on ordinary activities	60,554	1,081,935
Distribution under Gift Aid to parent undertaking	(60,554)	(1,081,935)
Retained earnings carried forward	-	-
The aggregate of the assets, liabilities and funds was		
Assets		1,744,143
Liabilities	-	(1,744,143)
Funds	-	-

Amounts owed to the parent undertaking are shown in note 14.

## Notes to the financial statements

For the year ended 31 December 2024

**13 Parent charity**

2024	2023
£	£

The parent charity's gross income and the results for the year are disclosed as follows

Gross income	3,286,990	4,225,596
Result for the year	(1,535,930)	(284,306)

**14 Debtors**

	The group		The charity	
	2024	2023	2024	2023
	£	£	£	£
Trade debtors	171,525	229,541	170,565	155,965
Other debtors	61,151	1,547,253	-	7,053
Prepayments and accrued income	1,182,240	382,207	839,720	1,113,465
Amounts due from group undertakings	-	-	1,171,536	1,626,936
The FIGO Charitable Foundation - USA	-	-	-	-
	<b>1,414,916</b>	<b>2,159,001</b>	<b>2,181,821</b>	<b>2,903,419</b>

**15 Creditors: amounts falling due within one year**

	The group		The charity	
	2024	2023	2024	2023
	£	£	£	£
Trade creditors	126,668	194,117	113,651	89,834
Taxation and social security	60,804	4,526	60,804	4,526
Other creditors	68,762	78	68,761	8,111
Accruals	144,808	177,887	122,758	164,970
Deferred income (note 16)	19,489	411,455	-	411,455
	<b>420,531</b>	<b>788,063</b>	<b>365,974</b>	<b>678,896</b>

**16 Deferred income**

	The group		The charity	
	2024	2023	2024	2023
	£	£	£	£
Balance at the beginning of the year	411,455	52,770	411,455	52,736
Amount released to income in the year	(411,455)	(888,227)	(411,455)	(888,193)
Amount deferred in the year	19,489	1,246,912	-	1,246,912
Balance at the end of the year	<b>19,489</b>	<b>411,455</b>	<b>-</b>	<b>411,455</b>

Notes to the financial statements

For the year ended 31 December 2024

**17a** Analysis of group net assets between funds (current year)

	Unrestricted General £	Unrestricted Designated £	Restricted funds £	Total funds £
Tangible fixed assets	-	1,005,617	-	<b>1,005,617</b>
Investments	3,188,007	-	-	<b>3,188,007</b>
Net current assets	1,920,581	-	2,781,660	<b>4,702,241</b>
Defined benefit pension liability	-	-	-	-
<b>Net assets at 31 December 2024</b>	<b>5,108,588</b>	<b>1,005,617</b>	<b>2,781,660</b>	<b>8,895,865</b>

**17b** Analysis of group net assets between funds (prior year)

	Unrestricted General £	Unrestricted Designated £	Restricted funds £	Total funds £
Tangible fixed assets	-	1,046,062	-	<b>1,046,062</b>
Investments	3,102,859	-	-	<b>3,102,859</b>
Net current assets	2,960,366	-	3,322,259	<b>6,282,625</b>
Defined benefit pension liability	-	-	-	-
<b>Net assets at 31 December 2024</b>	<b>6,063,225</b>	<b>1,046,062</b>	<b>3,322,259</b>	<b>10,431,546</b>

## Notes to the financial statements

For the year ended 31 December 2024

18a	Movements in funds (current year)				
		At 1 January	Expenditure		At 31 December
		2023	Income and gains	& losses	2024
		£	£	£	£
<b>Restricted funds:</b>					
Adenomyosis		7,756	-	-	7,756
Ask Dr FIGO - Silicon Valley Community		4,184	-	-	4,184
Accelerating Measurable Progress and Leveraging Investments for PostPartum Haemorrhage Impact (AMPLI-PPHI)'					-
Non Communicable Diseases		28,449	434,940	(442,871)	20,518
Fistula Activities - Combined Donor		201,371	-	-	201,371
Guidelines on prevention of Cervical Cancer - GSK Support Grant		677,122	290,315	(591,169)	376,268
Guidelines on prevention of Cervical Cancer - PATH Support Grant		46,732	-	-	46,732
GSK - Vaccination in women		79,865	-	-	79,865
Merck - Elimination of Cervical Cancer: Pilot Projects		7,331	-	-	7,331
ICI - International Childbirth Initiative		36,905	-	(20,000)	16,905
Markku Seppala Ovidon Lecture - Ovidon Trust Grant		(10,383)	1,237	-	(9,146)
Organisational capacity building - Bill and Melinda Gates Foundation Support Grant		163,388	-	-	163,388
Combating Postpartum Haemorrhage - Bill and Melinda Gates Foundation Support Grant					-
Advocating for Safe Abortion Project (ASA)		1,874,134	724,607	(960,012)	1,638,729
SRH Fund Donation		124,918	-	-	124,918
Ukraine Support Relief		(79,899)	613,317	(564,965)	(31,547)
Working Group on Challenges on care of women during labour and delivery		14,861	-	-	14,861
World Heath Organisation - WHO MEC Criteria		26,269	-	-	26,269
World Heath Organisation - WHO - Abortion and Contraception Care Together					-
Developing and publishing best practice advice		19,762	-	-	19,762
		3,644	-	(139)	3,505
		-	101,457	(127,316)	(25,859)
		95,850	-	-	95,850
<b>Total restricted funds</b>		<b>3,322,259</b>	<b>2,165,873</b>	<b>(2,706,472)</b>	<b>2,781,660</b>
<b>Unrestricted funds:</b>					
Designated Funds:					
President's fund		-	-	-	-
President's reallocated Fund to ICI		-	-	-	-
Fixed assets fund		1,046,062	-	(40,449)	1,005,613
<b>Total designated funds</b>		<b>1,046,062</b>	<b>-</b>	<b>(40,449)</b>	<b>1,005,613</b>
<b>General funds</b>		<b>6,063,225</b>	<b>1,516,170</b>	<b>(2,511,252)</b>	<b>5,108,592</b>
<b>Total unrestricted funds</b>		<b>7,109,287</b>	<b>1,516,170</b>	<b>(2,511,252)</b>	<b>6,114,205</b>
<b>Pension fund</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total funds including pension fund</b>		<b>10,431,546</b>	<b>3,682,043</b>	<b>(5,217,724)</b>	<b>8,895,865</b>

## Notes to the financial statements

For the year ended 31 December 2024

## 18a Movements in funds (prior year)

	At 1 January 2023	Income and gains	Expenditure & losses	Transfers	At 31 December 2023
	£		£	£	£
<b>Restricted funds:</b>					
Adenomyosis	10,108	-	(2,352)	-	7,756
Ask Dr FIGO - Silicon Valley Community	27,061	-	(22,877)	-	4,184
Accelerating Measurable Progress and Leveraging Investments for PostPartum Haemorrhage Impact (AMPLI-PPHI)'	47,999	364,484	(384,034)	-	28,449
Non Communicable Diseases	237,572	-	(36,201)	-	201,371
Fistula Activities - Combined Donor	631,411	610,301	(564,590)	-	677,122
Guidelines on prevention of Cervical Cancer - GSK Support Grant	46,732	-	-	-	46,732
Guidelines on prevention of Cervical Cancer - PATH Support Grant	79,865	-	-	-	79,865
GSK - Vaccination in women	11,692	-	(4,361)	-	7,331
Merck - Elimination of Cervical Cancer: Pilot Projects	36,905	-	-	-	36,905
ICI - International Childbirth Initiative	39,755	-	(50,138)	-	(10,383)
Markku Seppala Ovidon Lecture - Ovidon Trust Grant	163,388	-	-	-	163,388
Organisational capacity building - Bill and Melinda Gates Foundation Support Grant	1,685,883	1,100,802	(912,551)	-	1,874,134
Combating Postpartum Haemorrhage - Bill and Melinda Gates Foundation Support Grant	124,918	-	-	-	124,918
Prevention of Post Partum Haemorrhage - Concept Foundation	9,076	-	(9,076)	-	-
Advocating for Safe Abortion Project (ASA)	786,677	755,859	(1,622,435)	-	(79,899)
SRH Fund Donation	14,861	-	-	-	14,861
Ukraine Support Relief	26,269	-	-	-	26,269
Working Group on Challenges on care of women during labour and delivery	19,762	-	-	-	19,762
World Heath Organisation - WHO MEC Criteria	5,147	4,775	(6,278)	-	3,644
Developing and publishing best practice advice	95,850	-	-	-	95,850
<b>Total restricted funds</b>	<b>4,100,931</b>	<b>2,836,221</b>	<b>(3,614,893)</b>	<b>-</b>	<b>3,322,259</b>
<b>Unrestricted funds:</b>					
Designated Funds:					
President's fund	-	-	-	-	-
President's reallocated Fund to ICI	-	-	-	-	-
Fixed assets fund	1,083,223	-	-	(37,161)	1,046,062
<b>Total designated funds</b>	<b>1,083,223</b>	<b>-</b>	<b>-</b>	<b>(37,161)</b>	<b>1,046,062</b>
General funds	5,530,119	6,284,848	(5,788,903)	37,161	6,063,225
<b>Total unrestricted funds</b>	<b>6,613,342</b>	<b>6,284,848</b>	<b>(5,788,903)</b>	<b>-</b>	<b>7,109,287</b>
<b>Pension fund</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total funds including pension fund</b>	<b>10,714,273</b>	<b>9,121,069</b>	<b>(9,403,796)</b>	<b>-</b>	<b>10,431,546</b>

## 18 Explanation of fund transfer

### Purposes of restricted funds

#### Advocating for Safe Abortion Project

A grant provided by FJSI and Hewlett to support advocacy on safe abortion.

#### Adenomyosis - Menstrual Disorders Committee

A grant provided by AbbVie for the Adenomyosis Classification Project.

#### Congress USAid - Engender Health Support Grant

A grant provided by USAid-Engender Health for support for fellowships at the FIGO World Congress.

#### Fellowship Support Grant - Chien-Tien Hsu foundation

A grant made by the Chien-Tien Hsu Foundation to support FIGO's Fellowship Awards in Gynaecologic Oncology.

#### Fistula activities - Private Donor/Texas Children's Hospital & Anonymous Foundation and Hamlin Fistula Australia

Donations to support FIGO's fistula activities.

#### Fistula activities - Private Donor/Texas Children's Hospital

A donation made by a private individual and the Texas Children's hospital to support FIGO's fistula activities.

#### Guidelines on prevention of Cervical Cancer - GSK Support Grant

A grant provided by GSK to support the Charity's activities in the area of cervical cancer prevention, including the development and publication of guidelines for medical professionals.

#### Guidelines on prevention of Cervical Cancer - PATH Support Grant

A grant provided by PATH to support the Charity's activities in the area of cervical cancer prevention, including the development and publication of guidelines for medical professionals.

#### HPV - GSK Support Grant

A grant from GSK Biomedicals to support FIGO's work in the area of HPV being undertaken under the auspices of the FIGO Committee on Gynaecologic Oncology. As discussed with the donor, the unspent funds have been transferred to a new restricted fund to be spent on Vaccination in women.

#### HPV - Merck Support Grant

A grant from Merck & Co to support FIGO's work in the area of HPV being undertaken under the auspices of the FIGO Committee on Gynaecologic Oncology. As discussed with the donor, the unspent funds have been transferred to a new restricted fund to be spent on Elimination of cervical cancer.

#### GSK - Vaccination in women

A GSK donation to support vaccination of pregnant women.

#### Merck - Elimination of Cervical Cancer: Pilot Projects

A grant to support the undertaking of pilot projects to determine future directions in our aim to support work on the elimination of cervical cancer.

**18 Explanation of fund transfer (Continued)**

**Purposes of restricted funds (continued)**

**The International Childbirth Initiative (ICI)**

This is a FIGO Charity funded project to ensure evidence based practice focusing on better (bio)-medical and psychosocial health outcomes for the MotherBaby-Family unit.

**Markku Seppala Ovidon Lecture - Ovidon Trus**

A donation provided by the Ovidon Trust to support a key lecture within the FIGO World Congress Scientific Programme

**Prevention of Unsafe Abortion Working Group - Ipas support group**

A grant provided by Ipas to support the activities of the FIGO working group on the prevention of unsafe abortion.

**Prevention of Unsafe Abortion Working Group - US Donor Support grant**

A grant provided by a US donor foundation to support the activities of the FIGO working group on the prevention of unsafe abortion.

**WHO MEC Criteria**

A grant provided by WHO to provide policy and decision-makers, the scientific community, and providers with global standards for developing or updating national guidelines on contraceptive use.

**WHO project - Abortion and Contraception Care Together**

A collaboration with WHO (HRP) to work on disseminating and implementing WHO toolkits on FP and CAC competency based education.

**Working Group of Challenges in the care of women during labour and deliver**

This funding has been provided by five Corporate donors to support the development of evidence-based recommendations and tools for care of pregnant women during labour and delivery.

**World Report on Women's Health - Ipas Support Group**

A grant provided by Ipas to offset the costs of the World Report on Women's Health.

**WSRR - SOGC Support Grant**

A grant provided by SOGC (The Society of Obstetricians and Gynaecologists of Canada) to support the activities of the FIGO Committee for Women's Sexual and Reproductive Rights. The grant was originally provided to support the Pre Congress Workshop held in Santiago, Chile on 30-31 October, 2003 and follow up activities.

Notes to the financial statements

For the year ended 31 December 2024

---

19 Purposes of designated funds

President's fund

The trustees have decided to set aside funds to undertake women’s health projects.

Fixed assets fund

This fund represents the value of fixed assets not otherwise held within restricted funds. These have been designated as they are not freely available to be utilised for charitable activities.

Operating lease commitments payable as a lessee

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods.

	Equipment	
	2024	2023
	£	£
Less than one year	-	-
One to five years	5,732	7,165
	<u>5,732</u>	<u>7,165</u>

20 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.



## 21 Defined benefit pension scheme

FIGO participates in the Royal College of Obstetricians and Gynaecologists Pension Scheme (the scheme) a UK registered trust-based pension scheme that provides defined benefits linked to members' final pensionable salaries and their period of service as a member of the Scheme. The Scheme closed to future accrual of defined benefits with effect from 31 December 2014. The Trustees are responsible for running the scheme in accordance with the Scheme's Trust Deed and Rules, which sets out their powers. The Trustees of the Scheme are required to act in the best interests of the beneficiaries of the Scheme.

There are three categories of pension scheme members:

- \* In-service deferred members: currently employed by a participating employer. These members' pensions are based on their final pensionable salaries at retirement or earlier date of leaving the scheme
- \* Deferred members: those not currently employed by a participating employer and whose pension has not yet started
- \* Pensioner members: former members in receipt of pension

The Trustees are required to carry out an actuarial valuation of the scheme every 3 years. The last actuarial valuation of the Scheme was performed by the Scheme Actuary for the Trustees as at 1 April 2022. This valuation revealed a funding shortfall of £1.7 million. In respect of this deficit, the participating employers agreed to continue to pay contributions established following the 2019 actuarial valuation of £27,500 per month, with the final payment being made in the month ending 31 March 2023. These contributions have now ceased.

In addition, all professional expenses, costs associated with administering the Scheme and any levies (including the PPF Levy) are payable by the participating employers.

FIGO is responsible for meeting 6.75% of these expenses.

FIGO therefore does not expect to pay anything to the Scheme during the accounting period beginning 1 January 2025, other than its share of the contributions required to reimburse Scheme expenses.

Notes to the financial statements

For the year ended 31 December 2024

**21 Defined benefit pension scheme (continued)**

The employee benefit obligations recognised in the balance sheet are as follows:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Present value of funded obligation	(1,061)	(1,193)
Fair value of plan assets	1,106	1,263
Surplus /(Deficit) in scheme	<b>45</b>	<b>70</b>
<b>Amounts in the balance sheet:</b>		
Liabilities	(1,061)	(1,193)
Assets	1,106	1,263
Net Asset /(Liabilities)	45	70
Restriction to realisable amount	(45)	(70)
Recognised on the balance sheet	<b>0</b>	<b>0</b>

Amounts recognised in net incoming resources are as follows:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Administration expenses	39	16
Net interest expense	-	-
Total	<b>39</b>	<b>16</b>

Notes to the financial statements

For the year ended 31 December 2024

**21 Defined benefit pension scheme (continued)**

Changes in the present value of the defined benefit obligation are as follows:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Opening defined benefit obligation	(1,193)	(1,347)
Interest cost	(52)	(64)
Actuarial (gains)/losses - change of basis	111	4
Actuarial (gains)/losses - Experience	13	167
Other	-	-
Benefits paid	60	47
Closing defined benefit obligation	<b>(1,061)</b>	<b>(1,193)</b>

Changes in the fair value of plan assets are as follows:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Opening fair value of plan assets	1,263	1,428
Interest Income	55	67
Actuarial gains/(losses)	(128)	(175)
Contribution by employer	15	6
Other	(39)	(16)
Benefits paid	(60)	(47)
Closing fair value of plan assets	<b>1,106</b>	<b>1,263</b>

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Net position		
Opening net position	70	81
Interest Income	3	3
Actuarial gains	(4)	(4)
Restriction on realisable amount	(45)	(70)
Contribution by employer	15	6
Administrative expenses	(39)	(16)
Closing net position	-	-

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Net actuarial gain / (loss) on defined benefit pension scheme		
Actuarial gain/(loss) on plan obligations	124	171
Actuarial (loss)/gain on plan assets	(128)	(175)
Changes in limit on recognition of assets	28	15
	<b>24</b>	<b>11</b>

Notes to the financial statements

For the year ended 31 December 2024

**21 Defined benefit pension scheme**

Principal actuarial assumptions at the balance sheet date (expressed as weighted averages):

	<b>2024</b>	<b>2023</b>	<b>2022</b>
	%	%	%
Retail Price Inflation assumption	3.1%	3.0%	3.1%
Consumer Price Inflation assumption	2.8%	2.7%	2.7%
Discount rate at the end of the year	5.5%	4.5%	4.8%
Statutory revaluation in deferment	2.5%	2.5%	2.5%
Future salary increases	3.0%	3.0%	3.0%
Future pension increases	2.1% - 3.0%	2.1% - 2.9%	2.3% - 3.1%
Life expectancy - Male (individual age 60 in 2024)	26.0 years	26.0 years	26.6 years
Life expectancy - Male (individual age 40 in 2024)	27.6 years	27.6 years	28.1 years
Life expectancy - Female (individual age 60 in 2024)	28.8 years	28.8 years	29.2 years
Life expectancy - Female (individual age 40 in 2024)	30.3 years	30.3 years	30.7 years

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Total defined benefit (DB) assets		
Investment:		
Legal & General	15,965	18,567
Annuities	-	-
Trustee bank accounts/current assets	413	149
	<b>16,378</b>	<b>18,716</b>

Amounts for the current and previous years are as follows:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Defined benefit obligation	(1,061)	(1,193)
Plan assets	1,106	1,263
Surplus/(deficit)	45	70
Asset return less expected return on assets	(128)	(175)